Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as other finished forms, including lutein, and vitamins to food, dietary supplement, and feed manufacturers industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.

Revenue projections:

Revenue projections for DIVISLAB
Revenue projections for DIVISLAB

With Divi's Laboratories Limited's revenue forecasted to drop below last year's level, investors are expected to take a cautious stance. Such declines typically affect a company's bottom line, reducing profitability and making investors hesitant to invest heavily in the company until financial performance improves.

Financial Ratios:

currentRatio 6.943000
forwardPE 52.672558
debtToEquity 0.027000
earningsGrowth 0.231000
revenueGrowth 0.122000
grossMargins 0.602030
operatingMargins 0.301350
trailingEps 82.390000
forwardEps 56.300000

DIVISLAB's current ratio is 6.943, showing the company's capacity to service its short-term debt through its cash reserves and current assets. This is a positive indicator of liquidity, suggesting DIVISLAB has no trouble covering its short-term financial obligations.
DIVISLAB's forward PE is too high, potentially limiting future gains and posing a risk of a price correction. This valuation must be carefully considered with other fundamental metrics to evaluate whether the stock is worth its current price.
DIVISLAB's positive earnings and revenue growth reflect an optimistic outlook for the company's future. The growth in these key areas indicates that DIVISLAB is expected to continue expanding its business and boosting its financial performance in the coming periods.
DIVISLAB's positive gross and operating margins reflect strong profitability and operational efficiency. These metrics indicate the company's ability to control costs while maintaining healthy revenue, contributing to its solid financial performance.
DIVISLAB's forward EPS is lower than its trailing EPS, indicating the company may experience reduced profitability. This signals that the company's earnings growth could slow down in the near future.

Price projections:

Price projections for DIVISLAB
Price projections for DIVISLAB

Price projections for Divi's Laboratories Limited have gradually risen over time, signaling increased optimism about the company's future prospects. This steady upward revision reflects growing confidence in Divi's Laboratories Limited's market potential.

Insider Transactions:

Insider Transactions for DIVISLAB
Insider Transactions for DIVISLAB


26 sales of Divi's Laboratories Limited stock were made, with market price at 4988.3692626953125 per share.2 purchases of DIVISLAB stock were recorded, with market price of 5854.875 per share.Insider transactions show no strong upward or downward movement, offering little insight into the company's future performance or strategic direction.

Recommendation changes over time:

Recommendations trend for DIVISLAB
Recommendations trend for DIVISLAB


With analysts showing a buy bias for Divi's Laboratories Limited, investors may be more inclined to see the stock as an attractive investment. The favorable outlook could spur increased interest, positioning Divi's Laboratories Limited as a safe and profitable place for investors to allocate their funds and seek growth.